RASRAFMAPK

RASRAFMAPK, commonly referred to as the Ras-Raf-MEK-ERK signaling pathway, is a highly conserved signal transduction cascade that transmits extracellular signals from cell surface receptors to the nucleus to regulate gene expression, cell proliferation, differentiation, and survival. The core components are the Ras family small GTPases (HRAS, KRAS, NRAS); the RAF kinases (ARAF, BRAF, RAF1/c-RAF); MEK1/2 (MAP2K1/2); and ERK1/2 (MAPK3/1).

Activation begins at receptor tyrosine kinases (RTKs) upon ligand binding, leading to recruitment of adaptor proteins such as GRB2 and the guanine nucleotide exchange factor SOS. SOS facilitates loading of GTP onto Ras, producing active RAS-GTP. RAS-GTP promotes RAF recruitment and activation at the plasma membrane. Activated RAF phosphorylates MEK1/2, which in turn phosphorylates ERK1/2. Phosphorylated ERK translocates to the nucleus where it phosphorylates transcription factors such as ELK1 and components of AP-1, driving transcription of immediate-early genes and other downstream targets.

Regulation of the pathway involves control of RAS cycling by GEFs and GAPs, scaffolding proteins (e.g., KSR) that organize signaling complexes, and negative feedback loops. Crosstalk with other pathways, notably PI3K-AKT, modulates pathway output depending on cellular context.

Clinical significance is driven by frequent pathway dysregulation in cancer. Mutations in KRAS or BRAF can cause constitutive signaling independent of upstream cues. Therapeutic strategies include RAF inhibitors (e.g., vemurafenib, dabrafenib) and MEK inhibitors (e.g., trametinib), often used in combination to delay resistance. Resistance mechanisms include RTK upregulation and alternative signaling routes. The Ras-Raf-MEK-ERK axis remains a central focus of targeted cancer therapy and developmental biology research.